Halozyme Therapeutics Inc (NAS:HALO)
$ 48.13 0.1 (0.21%) Market Cap: 6.12 Bil Enterprise Value: 6.95 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 87/100

Halozyme Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 09:00PM GMT
Release Date Price: $23.78 (-1.49%)
Gregory Allen Harrison
BofA Merrill Lynch, Research Division - Research Analyst

Hello, everyone. Welcome to the afternoon session of Day 3 of the Bank of America Virtual Vegas Healthcare Conference. I'm Greg Harrison, U.S. biopharma analyst here at BofA, and I'm very excited that we have Halozyme with us here today. And here to speak on behalf of Halozyme is CEO, Helen Torley. The format is going to be a fireside chat. So feel free to send in questions, and I can ask them anonymously.

Questions & Answers

Gregory Allen Harrison
BofA Merrill Lynch, Research Division - Research Analyst

So Helen, let's just move right on to the Q&A. And maybe you could give the listeners, who maybe aren't as familiar, just an overview of as what is the ENHANZE technology? And how does the business model around that work?

Helen I. Torley
Halozyme Therapeutics, Inc. - President, CEO & Director

Yes. Thanks, Greg. I appreciate being here. So ENHANZE is Halozyme's proprietary enzyme, which is called rHuPH20. It is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot